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LETTERS TO THE EDITOR
Utility of a BNP as a Marker for RV
Dysfunction in Acute Pulmonary Embolism
We read with interest the study by Morrison et al. (1), in which it
was shown that rapid measurement of brain natriuretic peptide
(BNP) concentrations in blood is a sensitive and specific test for
differentiating patients with heart failure from those with primary
pulmonary causes of dyspnea in acute-care settings. The investi-
gators stated that correct, accurate and early diagnosis of left
ventricular (LV) dysfunction is imperative for improved survival.
However, recent data indicate that this statement also applies to
right ventricular (RV) dysfunction (2,3). The clinical diagnosis of
RV dysfunction, however, is usually more complex than that of LV
dysfunction. The RV function plays an important role in condi-
tions of increased pulmonary vascular resistance (such as pulmo-
nary embolism), resulting in increased workload of the RV and
eventually in RV dysfunction and failure. Right ventricular func-
tion may deteriorate with increase in RV afterload accompanied by
an increase in neurohormonal activation, but the increase of RV
systolic pressure will be limited (2,3). A suddenly increased
pressure load on the RV, is poorly tolerated because of the inability
of the normally thin-walled RV to develop and sustain high wall
tension and stress (3).
In two recent studies (2,3) we showed there was no correlation
between RV systolic pressure and BNP levels. In our opinion
(unpublished results involving 114 patients with acute pulmonary
embolism), patients with relatively low RV systolic pressure and
high BNP (above 180 pg/ml) are at imminent risk for RV failure.
Concerning prognosis and management of patients with acute
pulmonary embolism, BNP concentrations between 80 and 300
pg/ml are of particular interest (3). Indeed, low BNP levels have
excellent negative predictive value, and most patients with high
BNP levels probably have clinically manifest heart failure, leaving
patients with intermediate BNP levels in a “difficult to interpret”
zone. Serial BNP measurements in combination with echocardi-
ography should help to solve this important clinical problem.
We found significantly higher plasma BNP levels in patients
with RV dysfunction due to pulmonary embolism compared to
patients with pulmonary embolism and normal RV function (3).
Therefore, BNP is of clinical importance as a supplementary
tool for assessment of RV function and discrimination among
patients with normal RV function, RV dysfunction, and RV failure
under circumstances of acute RV pressure overload. This might
add to the purpose of the Morrison et al. (1) study and differentiate
heart failure from dyspnea of pulmonary etiologies even more
accurately.
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The Optimal “Dose” of Disease Management
Programs in HF
Dr. Krumholz and his colleagues are to be congratulated with their
effects of a targeted education and support intervention on the rate
of readmission or death and hospital cost in patients with heart
failure (HF) (1). This study adds to the understanding that
education and support should be a component of an intervention
program for HF patients. As noted by the investigators, there is
evidence that multidisciplinary HF programs may improve patient
outcomes in respect to health care utilization, costs and quality of
life (2). Key components recognized by the American Heart
Association include education and advice, availability of health
care providers, counselling after discharge and optimal medical
therapy (3). Studies that established the effect of separate compo-
nents are scarce, and Krumholz et al. (1) showed that education
and support alone can substantially improve outcome. Most
groups, however, argue that both components (i.e., pharmacologic
and nonpharmacologic HF management strategies) are required
(4).
In the Krumholz et al. study (1), patients were educated in an
hour-long face-to-face session, with intensive monitoring after
discharge. Previous data indicate that intensive education during
hospitalization with only one outpatient follow-up visit is not
sufficient to reduce rehospitalization (5). In a similar study with
two follow-up outpatient visits, however, Cline et al. (6) were able
to demonstrate a significant benefit from the intervention.
The question then is this: How intense should an HF program
be? To date, there are no studies that compare the relative
effectiveness of different programs. For this reason, we have
recently started a multicenter randomized trial in the Netherlands
that will include 1,050 HF patients. In this Coordinating study
evaluating Outcomes of Advising and Counseling in Heart Failure
(COACH), patients are randomized into three arms: 1) care as
usual, 2) basic education and support, and 3) intensive education
and support; patients will be followed for at least two years.
Outcomes of this study are time to first major event (HF
hospitalizations and death), quality of life and costs. With this trial
we aim to derive insight into the optimal dose of an HF interven-
tion, enabling us to make rational and responsible choices in the
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